‘End of the Road’ for Trabectedin in Ovarian Cancer?
March 21, 2019 7:00 pmBy Ian Ingram
Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.
Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more